Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.510
-0.030 (-1.95%)
At close: Feb 3, 2026, 4:00 PM EST
1.465
-0.045 (-3.01%)
After-hours: Feb 3, 2026, 7:16 PM EST
Geron Employees
Geron had 229 employees as of December 31, 2024. The number of employees increased by 88 or 62.41% compared to the previous year.
Employees
229
Change (1Y)
88
Growth (1Y)
62.41%
Revenue / Employee
$800,886
Profits / Employee
-$349,301
Market Cap
963.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 229 | 88 | 62.41% | 229 | 0 |
| Dec 31, 2023 | 141 | 34 | 31.78% | 141 | 0 |
| Dec 31, 2022 | 107 | 35 | 48.61% | 107 | 0 |
| Dec 31, 2021 | 72 | 17 | 30.91% | 69 | 3 |
| Dec 31, 2020 | 55 | 9 | 19.57% | 53 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ARS Pharmaceuticals | 167 |
| CytomX Therapeutics | 121 |
| Nanobiotix | 103 |
| Annexon | 99 |
| Theravance Biopharma | 97 |
| Ventyx Biosciences | 83 |
| ArriVent BioPharma | 52 |
| GH Research | 50 |
GERN News
- 7 days ago - Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade) - Seeking Alpha
- 22 days ago - Geron Corporation Provides 2026 Financial Guidance - GlobeNewsWire
- 6 weeks ago - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation - GlobeNewsWire
- 2 months ago - Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS - GlobeNewsWire
- 3 months ago - Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help - Seeking Alpha
- 3 months ago - Geron Corporation (GERN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire